abstract |
The present disclosure relates to novel pharmaceutical compositions for active pharmaceutical ingredients subject to first pass metabolism. More particularly, bumetanide analogs, including bumetanide dibenzylamide, bumetanide diethylamide, and bumetanide morpholinoamide, are demonstrated as susceptible to first pass metabolism, thereby prompting effort toward developing an acceptable pharmaceutical formulation to provide adequate bioavailability. |